Fig. 10.

BRD4 controls TGF-β-induced pulmonary fibrotic program in vivo. Eighteen-week-old C57B6 mice were pretreated ± JQ1 (50 mg/kg body wt ip) and given repetitive intranasal challenges with TGF-β (1 μg/mouse every other day for 30 days). A: activation of the fibrotic program. Q-RT-PCR for mCol1A1, mFN1, mSNAI1, mVIM, mαSMA, and mIL-6 mRNAs was performed in total lung RNA. *P < 0.01 compared to without JQ1 from n = 5 experiments. B: expression of the mesenchymal transition. Paraffin-embedded lung sections were immunostained for mesenchymal markers SNAI1, VIM, FN1, and COL1A as well as BRD4 activation marker H3K122ac, detected with secondary Alexa Fluor 488 (green)- or 568 (red)-conjugated goat anti-rabbit IgG respectively, counterstained with DAPI, and imaged via confocal fluorescence microscopy. Images are at ×63 magnification. Data representative of n = 5 experiments.